1. Home
  2. VRNA vs WCC Comparison

VRNA vs WCC Comparison

Compare VRNA & WCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRNA
  • WCC
  • Stock Information
  • Founded
  • VRNA 2005
  • WCC 1922
  • Country
  • VRNA United Kingdom
  • WCC United States
  • Employees
  • VRNA N/A
  • WCC N/A
  • Industry
  • VRNA Biotechnology: Pharmaceutical Preparations
  • WCC Telecommunications Equipment
  • Sector
  • VRNA Health Care
  • WCC Consumer Discretionary
  • Exchange
  • VRNA Nasdaq
  • WCC Nasdaq
  • Market Cap
  • VRNA 8.3B
  • WCC 8.1B
  • IPO Year
  • VRNA 2017
  • WCC 1999
  • Fundamental
  • Price
  • VRNA $94.58
  • WCC $186.40
  • Analyst Decision
  • VRNA Strong Buy
  • WCC Buy
  • Analyst Count
  • VRNA 8
  • WCC 8
  • Target Price
  • VRNA $105.38
  • WCC $212.63
  • AVG Volume (30 Days)
  • VRNA 1.2M
  • WCC 588.5K
  • Earning Date
  • VRNA 08-07-2025
  • WCC 07-31-2025
  • Dividend Yield
  • VRNA N/A
  • WCC 0.98%
  • EPS Growth
  • VRNA N/A
  • WCC 10.34
  • EPS
  • VRNA N/A
  • WCC 13.26
  • Revenue
  • VRNA $118,535,000.00
  • WCC $21,812,500,000.00
  • Revenue This Year
  • VRNA $891.79
  • WCC $4.26
  • Revenue Next Year
  • VRNA $78.94
  • WCC $4.26
  • P/E Ratio
  • VRNA N/A
  • WCC $14.01
  • Revenue Growth
  • VRNA N/A
  • WCC N/A
  • 52 Week Low
  • VRNA $14.15
  • WCC $125.21
  • 52 Week High
  • VRNA $99.01
  • WCC $216.17
  • Technical
  • Relative Strength Index (RSI)
  • VRNA 68.57
  • WCC 64.08
  • Support Level
  • VRNA $92.88
  • WCC $181.80
  • Resistance Level
  • VRNA $99.01
  • WCC $177.63
  • Average True Range (ATR)
  • VRNA 3.09
  • WCC 4.27
  • MACD
  • VRNA -0.40
  • WCC 0.74
  • Stochastic Oscillator
  • VRNA 69.04
  • WCC 97.52

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

About WCC WESCO International Inc.

Wesco can be traced back to the late 1800s but was officially founded in 1922, acting as the distribution arm of Westinghouse Electric. Throughout the 1900s, Wesco entered and subsequently exited the consumer electronics, transit, bottling, and nuclear plant distribution markets. It was sold to a private equity firm in 1994 and then went public in 1999, and numerous acquisitions have since been made to fill the gaps in Wesco's geographical and product coverage. Today, the firm primarily distributes electrical, networking, security, and utility equipment used in the construction and repair of structures such as offices, data centers, power transmission lines, and manufacturing plants. Wesco has operations around the globe but generates the majority of its revenue in the United States.

Share on Social Networks: